Logo image of CNTG

CENTOGENE NV (CNTG) Stock Fundamental Analysis

NASDAQ:CNTG - Nasdaq - NL0014040206 - Common Stock - Currency: USD

0.325  -0.02 (-6.23%)

After market: 0.351 +0.03 (+8%)

Fundamental Rating

1

Overall CNTG gets a fundamental rating of 1 out of 10. We evaluated CNTG against 106 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of CNTG have multiple concerns. CNTG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTG had negative earnings in the past year.
In the past year CNTG has reported a negative cash flow from operations.
CNTG had negative earnings in each of the past 5 years.
CNTG had negative operating cash flow in 4 of the past 5 years.
CNTG Yearly Net Income VS EBIT VS OCF VS FCFCNTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M

1.2 Ratios

With a Return On Assets value of -46.05%, CNTG is not doing good in the industry: 85.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -46.05%
ROE N/A
ROIC N/A
ROA(3y)-43.71%
ROA(5y)-32.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTG Yearly ROA, ROE, ROICCNTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300 -400

1.3 Margins

CNTG's Gross Margin of 36.46% is fine compared to the rest of the industry. CNTG outperforms 63.79% of its industry peers.
In the last couple of years the Gross Margin of CNTG has declined.
The Profit Margin and Operating Margin are not available for CNTG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.22%
GM growth 5Y-6.4%
CNTG Yearly Profit, Operating, Gross MarginsCNTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

0

2. Health

2.1 Basic Checks

CNTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CNTG has been increased compared to 1 year ago.
The number of shares outstanding for CNTG has been increased compared to 5 years ago.
Compared to 1 year ago, CNTG has a worse debt to assets ratio.
CNTG Yearly Shares OutstandingCNTG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CNTG Yearly Total Debt VS Total AssetsCNTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -1.03, we must say that CNTG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.03, CNTG is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.03
ROIC/WACCN/A
WACC7.5%
CNTG Yearly LT Debt VS Equity VS FCFCNTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.02 indicates that CNTG should not have too much problems paying its short term obligations.
With a Current ratio value of 1.02, CNTG is not doing good in the industry: 68.10% of the companies in the same industry are doing better.
CNTG has a Quick Ratio of 1.02. This is a bad value and indicates that CNTG is not financially healthy enough and could expect problems in meeting its short term obligations.
CNTG's Quick ratio of 0.96 is on the low side compared to the rest of the industry. CNTG is outperformed by 62.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.96
CNTG Yearly Current Assets VS Current LiabilitesCNTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

CNTG shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.92%.
The Revenue has been growing slightly by 2.25% in the past year.
The Revenue has been growing slightly by 3.70% on average over the past years.
EPS 1Y (TTM)-6.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.92%
Revenue 1Y (TTM)2.25%
Revenue growth 3Y8.07%
Revenue growth 5Y3.7%
Sales Q2Q%254.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.37%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTG Yearly Revenue VS EstimatesCNTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CNTG Yearly EPS VS EstimatesCNTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTG Price Earnings VS Forward Price EarningsCNTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTG Per share dataCNTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTOGENE NV

NASDAQ:CNTG (8/7/2024, 8:06:53 PM)

After market: 0.351 +0.03 (+8%)

0.325

-0.02 (-6.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)06-17 2024-06-17
Earnings (Next)09-04 2024-09-04
Inst Owners0.09%
Inst Owner Change-99.99%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.97M
Analysts82.86
Price Target1.53 (370.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS1.94
BVpS-1.01
TBVpS-1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.46%
FCFM N/A
ROA(3y)-43.71%
ROA(5y)-32.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.22%
GM growth 5Y-6.4%
F-Score2
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.95%
Cap/Sales 4.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.96
Altman-Z -1.03
F-Score2
WACC7.5%
ROIC/WACCN/A
Cap/Depr(3y)25.62%
Cap/Depr(5y)60.29%
Cap/Sales(3y)7.53%
Cap/Sales(5y)16.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.92%
EPS Next Y39.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.25%
Revenue growth 3Y8.07%
Revenue growth 5Y3.7%
Sales Q2Q%254.74%
Revenue Next Year22.37%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.85%
OCF growth 3YN/A
OCF growth 5YN/A